Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00441597
Status:
COMPLETED
Last Update Posted:
2009-03-17
First Post:
2007-02-28
Brief Title:
Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo
Sponsor:
Radboud University Medical Center
Organization:
Radboud University Medical Center
Study Overview
Official Title:
Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To study the impact of 3 day exposure to atorvastatin 80mg on Annexin A5 targeting after ischemic exercise in the non-dominant forearm
Detailed Description:
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors also known as statins have been found to reduce cardiovascular events This protective effect has been traditionally explained by lowering plasma cholesterol and subsequent reduced progression of atherosclerosis However in animal experiments statins have also shown the ability to induce pharmacologic preconditioning and thereby reduce infarct size This effect contributes to the beneficial effect of statins on reducing of cardiovascular events In order to differentiate between these two mechanisms of protection we will study the effect of atorvastatin on ischemia reperfusion damage after a short exposure to atorvastatin before the lipid lowering effect of atorvastatin becomes apparent
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None